Senicapoc Chemical Properties

Melting point:

180-181 °C(Solv: hexane (110-54-3); dichloromethane (75-09-2))

Boiling point:

460.7±45.0 °C(Predicted)

Density 

1.250±0.06 g/cm3(Predicted)

storage temp. 

Sealed in dry,Store in freezer, under -20°C

solubility 

DMSO : 50 mg/mL (154.64 mM; Need ultrasonic)

form 

Powder

pka

15.41±0.50(Predicted)

color 

White to yellow

InChI

InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)

InChIKey

SCTZUZTYRMOMKT-UHFFFAOYSA-N

SMILES

C(C1C=CC=CC=1)(C1C=CC(F)=CC=1)(C1C=CC(F)=CC=1)C(=O)N

Senicapoc Usage And Synthesis

Description

Senicapoc is an inhibitor of intermediate conductance calcium-activated potassium (IK_Ca1/K_Ca3.1) channels. It inhibits rubidium efflux from and dehydration of isolated human red blood cells (RBCs) induced by the calcium ionophore A23187 (; IC₅₀s = 11 and 30 nM, respectively). Senicapoc (10 mg/kg twice per day) reduces IK_Ca1/K_Ca3.1 channel activity, increases potassium levels in RBCs, and decreases erythrocyte density in the SAD transgenic mouse model of sickle cell disease. It inhibits IL-2, IFN-γ, IL-12, and IL-17A production in CD3⁺ T cells stimulated with phorbol 12-myristate 13-acetate (PMA; ) and ionomycin (Item Nos. 10004974 | 11932) when used at a concentration of 1 μM. Senicapoc (100 mg/kg) increases the paw withdrawal threshold in a rat model of chronic constriction injury (CCI) of the sciatic nerve.

Uses

Treatment of disorders mediated by a calcium activated intermediate conductance potassium ion channel antagonist.

Definition

Senicapoc (ICA-17043; bis(4-fluorophenyl)phenyl acetamide), a selective, highly potent Gardos channel blocker (IC50 = 11 nM), specifically inhibits the efflux of potassium from the RBCs of both SCD transgenic mice and human sickle cell disease patients. It is derived from clotrimazole-1, a KCNN4 inhibitor. Senicapoc is well tolerated by both healthy volunteers and patients with SCD and has favourable pharmacokinetics, with a long half-life permitting once-daily dosing. It was designed for long-term sickle cell disease therapy to avoid clotrimazole-1 side effects. Whereas Senicapoc is a potent inhibitor of WT KCNN4, its efficiency on mutated channels was unknown[1-2].

References

[1] Raphael Rapetti-Mauss. “Senicapoc: a potent candidate for the treatment of a subset of hereditary xerocytosis caused by mutations in the Gardos channel.” Haematologica 101 11 (2016): e431–e435.
[2] Kenneth I Ataga. “Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.” Blood (2008): 3991–7.

Senicapoc(289656-45-7)Related Product Information

• 2-FLUOROPHENYL CYCLOPENTYL KETONE
• 2,6-Difluorobenzamide
• 2,2-bis(4-fluorophenyl)-2-phenyl-acetamide